Pharmosa Biopharm (ROCO:6875) Cash-to-Debt : 14.04 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Pharmosa Biopharm Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Pharmosa Biopharm's cash to debt ratio for the quarter that ended in Mar. 2024 was 14.04.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Pharmosa Biopharm could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Pharmosa Biopharm's Cash-to-Debt or its related term are showing as below:

ROCO:6875' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03 Med: 7.05 Max: 31.73
Current: 14.04

During the past 6 years, Pharmosa Biopharm's highest Cash to Debt Ratio was 31.73. The lowest was 0.03. And the median was 7.05.

ROCO:6875's Cash-to-Debt is ranked better than
60.35% of 1526 companies
in the Biotechnology industry
Industry Median: 6.315 vs ROCO:6875: 14.04

Pharmosa Biopharm Cash-to-Debt Historical Data

The historical data trend for Pharmosa Biopharm's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Pharmosa Biopharm Cash-to-Debt Chart

Pharmosa Biopharm Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.03

3.33

12.44

31.73

6.75

Pharmosa Biopharm Quarterly Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial									N/A	6.72	7.54	6.75	14.04

Competitive Comparison of Pharmosa Biopharm's Cash-to-Debt

For the Biotechnology subindustry, Pharmosa Biopharm's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmosa Biopharm's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmosa Biopharm's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Pharmosa Biopharm's Cash-to-Debt falls into.

Pharmosa Biopharm Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Pharmosa Biopharm's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	974.059	/	(25.954	+	118.415)
	=	6.75

Pharmosa Biopharm's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1865.376	/	(18.807	+	114.026)
	=	14.04

Pharmosa Biopharm (ROCO:6875) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Pharmosa Biopharm Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Pharmosa Biopharm's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmosa Biopharm (ROCO:6875) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmosa Biopharm Inc (ROCO:6875) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.66, Sanchong Road, Nangang District, Taipei, TWN, 11502

Website

https://www.pharmosa.com.tw

Pharmosa Biopharm Inc is a world-class biotechnology company focusing on developing a new drug by exploiting proprietary formulation and manufacturing technology.

Pharmosa Biopharm (ROCO:6875) Headlines

No Headlines